Liver, Phase I-II
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jade Vanacore
- James Vredenburgh, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- John Kunstman, MD, MHS, FACS
- Jose Morales-Marin
- Justin Persico, MD
- Katelyn Scott
- Kert Sabbath, MD, FACP
- Laura Sabourin
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Michael Grant, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Sara Anastasio, RN
- Sharynn Hall, MD, PhD
- Su Hsien Lim, MD
- Teresa White
- Vanna Dest
- Victor Chang, MD
- Vidya Kesavan
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated08/06/2024
- Study HIC#2000035308